Clinical trial · Interventional
Ultra-low Dose Bevacizumab Plus Temozolomide for Recurrent High-grade Gliomas
NCT02416999CI-TRIAL-00020983unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is to evaluate the effectiveness of ultra-low dose Bevacizumab plus Temozolomide for recurrent high-grade gliomas.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Recurrent High-grade Glioma | High-Grade Glioma, NOS | CURATED_BROADER | 0.78 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Temozolomide | Drug | Temozolomide | ALIAS |
| Ultra-low dose Bevacizumab | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- patient group
- interventionNames
- Drug: Ultra-low dose Bevacizumab
- Drug: Temozolomide
Primary outcomes (2)
- measure
- 6-month survival rate of recurrent glioblastoma multiforme patients under ultra-low dose Bevacizumab plus Temozolomide treatment
- timeFrame
- 6 months
- measure
- 12-month survival rate of recurrent WHO-III glioma patients under ultra-low dose Bevacizumab plus Temozolomide treatment
- timeFrame
- 12 months
Secondary outcomes (6)
- measure
- Overall survival of recurrent glioblastoma multiforme patients under ultra-low dose Bevacizumab plus Temozolomide treatment
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * High grade glioma was diagnosed by post-operation pathological method, and shows a relapse. * Before included, the patient needs imageological examinations, and the diameter of contrast enhancing area is bigger than 1cm, PET or MRS results show positive features. * The age of patient should be between 18 years old and 70 years old. * The condition of the patient permits the treatment of ultra-low dose Bevacizumab plus Temozolomide. * The patient is informed consent,and willing to join in this research. Exclusion Criteria: * The diagnosis is not recurrent high-grade glioma. * The diagnosis of high-grade glioma was not established by pathological method. * The results of imageological examinations do not meet the standard of including. * The age of the patient does not meet the requirement of this research. * The condition of the patient does not permit the treatment of ultra-low dose Bevacizumab plus Temozolomide. * There are other conditions that the clinicians believe that the treatment of ultra-low dose Bevacizumab plus Temozolomide is not appropriate for the patient. * The patient is not willing to join in this research.
References
Publications (0)
Data not yet available
No reference posted for this study.